US Representative

Clay Higgins Authored & Sponsored Legislation

Session

Co-Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB563

Introduced
1/20/25  
No Retaining Every Gun In a System That Restricts Your Rights Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB578

Introduced
1/21/25  
Sarah's LawThis bill requires the Department of Justice or the Department of Homeland Security (DHS) to detain a non-U.S. national (alien under federal law) who is unlawfully present in the United States and has been charged with, arrested for, convicted of, or admits to having committed acts that constitute the essential elements of a crime that resulted in the death or serious bodily injury of another person.DHS must obtain information about the identity of any victims of the crimes for which the detained individual was charged or convicted. DHS shall provide the victim, or a relative or guardian of a deceased victim, with information about the detained individual, including name, date of birth, nationality, immigration status, criminal history, and a description of any related removal efforts.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB589

Introduced
1/21/25  
FACE Act Repeal Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB6

Introduced
1/3/25  
Family and Small Business Taxpayer Protection Act This bill rescinds unobligated funds that were provided by the Inflation Reduction Act of 2022 to the Internal Revenue Service (IRS) for enforcement activities related to the determination and collection of taxes, for operations support for taxpayer services and enforcement activities, and for a task force to research options for a free, direct electronic filing (e-filing) tax return system. The bill also rescinds unobligated funds that were provided by the Inflation Reduction Act of 2022 for expenses of theTreasury Inspector General for Tax Administration,Office of Tax Policy,U.S. Tax Court, andoffices within the Department of the Treasury that provide oversight and support for the IRS.  
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB632

Introduced
1/22/25  
Protecting Life on College Campus Act of 2025This bill prohibits the award of federal funds to an institution of higher education (IHE) that hosts or is affiliated with a school-based service site that provides abortion drugs or abortions to its students or to employees of the IHE or the site. An IHE that hosts or is affiliated with a site must, in order to remain eligible for federal funds, annually certify that the site does not provide abortion drugs or abortions to students or employees.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB633

Introduced
1/22/25  
Refer
1/22/25  
TAKE IT DOWN Act Tools to Address Known Exploitation by Immobilizing Technological Deepfakes On Websites and Networks Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB645

Introduced
1/23/25  
National Constitutional Carry Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB648

Introduced
1/23/25  
Strengthening our Servicemembers with Milk Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB650

Introduced
1/23/25  
Families’ Rights and Responsibilities Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB679

Introduced
1/23/25  
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.